VEGF Signaling and Targeted Therapies in Cancer: Molecular Mechanisms, Clinical Applications, Resistance, and Cardiorenal Toxicities
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27209376 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Abhishek Mishra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72203, USA. Hauptthemen laut MEDLINE: Neoplasms, Signal Transduction, Molecular Targeted Therapy, Vascular Endothelial Growth Factor A. Die Arbeit nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Vascular endothelial growth factor (VEGF) signaling is a central regulator of tumor angiogenesis and a major therapeutic target in oncology. VEGF-neutralizing agents and VEGF receptor tyrosine kinase inhibitors (VEGFR-TKIs) confer clinical benefit in multiple solid malignancies, but resistance and cardiovascular and renal toxicities can limit durable treatment. This review summarizes VEGF ligands, VEGF receptors, and the principal signaling mechanisms relevant to angiogenesis and lymphangiogenesis, with emphasis on VEGFR2 and VEGFR3 biology. We then examine established VEGF-targeted therapies, representative clinical evidence for VEGFR-TKIs, mechanisms of therapeutic resistance, and VEGF inhibitor-associated hypertension, endothelial dysfunction, proteinuria, and kidney injury. Particular attention is given to strategies for improving the therapeutic index of VEGF pathway inhibition, including risk assessment and toxicity monitoring, immunotherapy combinations, and emerging mechanism-based approaches. Modulation of the epoxyeicosatrienoic acid (EET)/soluble epoxide hydrolase axis is discussed as a promising experimental strategy for cardiorenal protection; however, current support is predominantly preclinical and requires clinical validation. Integrating tumor vascular biology with mechanisms of normal vascular and renal homeostasis may facilitate safer and more effective VEGF-directed cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72203, USA.
- Arkansas Children's Hospital, Little Rock, AR 72202, USA.
ORCID-Profile: Abhishek Mishra, Md Abdul Hye Khan, John D Imig
Zitieren
APA
Mishra, A., Khan, M. A. H., Jamal, R., Kadhim, I., & Imig, J. D. (2026). VEGF Signaling and Targeted Therapies in Cancer: Molecular Mechanisms, Clinical Applications, Resistance, and Cardiorenal Toxicities. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27209376
Vancouver
Mishra A, Khan MAH, Jamal R, Kadhim I, Imig JD. VEGF Signaling and Targeted Therapies in Cancer: Molecular Mechanisms, Clinical Applications, Resistance, and Cardiorenal Toxicities. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27209376
BibTeX
@article{Mishra2026,
author = {Mishra, Abhishek and Khan, Md Abdul Hye and Jamal, Ripa and Kadhim, Ilham and Imig, John D},
title = {VEGF Signaling and Targeted Therapies in Cancer: Molecular Mechanisms, Clinical Applications, Resistance, and Cardiorenal Toxicities},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27209376}
}
EUVIMED